Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New Horizons Study
ISRCTN57583139Phase 4Active, not recruiting
- Sponsor
- King's Health Partners
- Start
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of rivaroxaban and edoxaban in venous thromboembolism (VTE) (2 arms), sponsored by King's Health Partners. Primary endpoints: Edoxaban plasma and breastmilk concentrations and Rivaroxaban plasma and breastmilk concentrations. Started Apr 2023; status: active, not recruiting.
02
Drugs
rivaroxabanedoxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ISRCTN57583139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN57583139.